Glenmark Pharmaceuticals planning to file close to 20-25 ANDAs each year

19 Sep 2017 Evaluate

Glenmark Pharmaceuticals is planning to file close to 20-25 Abbreviated New Drug Applications (ANDAs) each year over the next five years and launch 10-20 products annually. The company’s pipeline of specialty products, to be rolled out over the next 3-4 years, is expected to act as a defence against generic price erosion and increase in competition, and boost profitable growth.

Glenmark’s current portfolio consists of 124 products authorized for distribution in the US marketplace and 62 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.



Glenmark Pharma Share Price

1974.05 17.65 (0.90%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×